Peter Melnyk, Novocure’s chief commercial officer is set to step down from 15 March this year.
Melnyk joined the oncology specialist in 2011, taking on responsibility for its global marketing and sales efforts.
Previously, he was senior vice president for sales and marketing at OSI Pharmaceuticals, where he led the global commercialisation of Tarceva (erlotinib) from 2003 to 2011.
Prior to this, Melnyk served as executive director of oncology at Pfizer and a director of oncology at Bristol-Myers Squibb.
Asaf Danziger, Novocure’s chief executive officer, said: “I want to thank Peter for his more than five years of leadership at Novocure.
“During his tenure, Peter developed our commercial business model, launched the Optune brand and drove eight consecutive quarters of active patient and revenue growth after the presentation of our EF-14 clinical data in Q4 2014.
“Peter leaving our commercial organisation in a strong position to continue its success. I look forward to following Peter’s continued accomplishments as he begins the next chapter of his career.”